Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › Microarrays & Multiplexing › Illumina Awarded $26.7M in NIPT Patent Suit Against Ariosa

Illumina Awarded $26.7M in NIPT Patent Suit Against Ariosa

Jan 26, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Illumina has won a patent infringement lawsuit against Roche's Ariosa Diagnostics related to the companies' noninvasive prenatal tests. A jury in the US District Court of the Northern District of California awarded Illumina $26.7 million in damages.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

  2. Illumina to Acquire Grail for $8B in Cash and Stock

  3. CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

  4. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  5. FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.